Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CYP2C19 Genotype as a Predictor of Gastric Acid Suppression and Healing of Erosive Esophagitis

NCT01824199 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT01824199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01824199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CYP2C19 Genotype as a Predictor of Gastric Acid Suppression and Healing of Erosive Esophagitis
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Withdrawn
Start date
March 31, 2013
Completion date
November 30, 2016
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophagitis